{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:16:29Z","timestamp":1794539789398,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Perinatol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Extremely low gestational age newborns (ELGANs) represent an especially vulnerable population. Herein, we aimed to determine incidence and severity of pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) in extremely immature ELGANs (gestational age: 23<jats:sup>0\/6<\/jats:sup>\u201325<jats:sup>6\/7<\/jats:sup> weeks).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective observational cohort study, we assessed BPD-PH by means of several echocardiography markers and serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at 3 and 12 months of chronological age. In addition, we analyzed incidence and efficacy of pharmacologic treatment for BPD-PH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At 3 months 15\/34 ELGANs had echocardiographic evidence of BPD-PH, while at 12 months of age 6\/34 still had PH. PH-targeted therapy consisted of sildenafil monotherapy in 11 and dual oral combination therapy (sildenafil and macitentan) in four ELGANs at 3 and 12 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>44% (15\/34) of ELGANs developed BPD-PH. All received PH-targeted pharmacotherapy at 3 months, leading to hemodynamic improvements at 12 months in most infants.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41372-022-01374-w","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:19:26Z","timestamp":1648808366000},"page":"781-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Extremely premature infants born at 23\u201325 weeks gestation are at substantial risk for pulmonary hypertension"],"prefix":"10.1038","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-5379","authenticated-orcid":false,"given":"Hannes","family":"Sallmon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Koestenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-5763","authenticated-orcid":false,"given":"Alexander","family":"Avian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Reiterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5499-3712","authenticated-orcid":false,"given":"Bernhard","family":"Schwaberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Meinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Cvirn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kurath-Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Gamillscheg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"1374_CR1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1053\/j.semperi.2018.09.005","volume":"42","author":"SK Berkelhamer","year":"2018","unstructured":"Berkelhamer SK, Mestan KK, Steinhorn R. An update on the diagnosis and management of bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension. Semin Perinatol. 2018;42:432\u201343.","journal-title":"Semin Perinatol"},{"key":"1374_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1164\/rccm.201409-1594OC","volume":"191","author":"PM Mourani","year":"2015","unstructured":"Mourani PM, Sontag MK, Younoszai A, Miller JI, Kinsella JP, Baker CD, et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2015;191:87\u201395.","journal-title":"Am J Respir Crit Care Med"},{"key":"1374_CR3","doi-asserted-by":"publisher","first-page":"L1239","DOI":"10.1152\/ajplung.00268.2015","volume":"309","author":"DM Silva","year":"2015","unstructured":"Silva DM, Nardiello C, Pozarska A, Morty RE. Recent advances in the mechanisms of lung alveolarization and the pathogenesis of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2015;309:L1239\u201372.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1374_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41390-020-0993-4","volume":"89","author":"G Hansmann","year":"2021","unstructured":"Hansmann G, Sallmon H, Roehr CC, Kourembanas S, Austin ED, Koestenberger M. European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr Res. 2021;89:446\u201355.","journal-title":"Pediatr Res"},{"key":"1374_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/MOP.0000000000000355","volume":"28","author":"MG O\u2019Connor","year":"2016","unstructured":"O\u2019Connor MG, Cornfield DN, Austin ED. Pulmonary hypertension in the premature infant: a challenging comorbidity in a vulnerable population. Curr Opin Pediatr. 2016;28:324\u201330.","journal-title":"Curr Opin Pediatr"},{"key":"1374_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.clp.2015.08.010","volume":"42","author":"PM Mourani","year":"2015","unstructured":"Mourani PM, Abman SH. Pulmonary hypertension and vascular abnormalities in bronchopulmonary dysplasia. Clin Perinatol. 2015;42:839\u201355.","journal-title":"Clin Perinatol"},{"key":"1374_CR7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1542\/peds.2007-0971","volume":"120","author":"E Khemani","year":"2007","unstructured":"Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120:1260\u20139.","journal-title":"Pediatrics."},{"key":"1374_CR8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1164\/ajrccm.163.7.2011060","volume":"163","author":"AH Jobe","year":"2001","unstructured":"Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1374_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1164\/rccm.201812-2348OC","volume":"200","author":"EA Jensen","year":"2019","unstructured":"Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. Am J Respir Crit Care Med. 2019;200:751\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1374_CR10","doi-asserted-by":"publisher","first-page":"1801916","DOI":"10.1183\/13993003.01916-2018","volume":"53","author":"EB Rosenzweig","year":"2019","unstructured":"Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53:1801916.","journal-title":"Eur Respir J"},{"key":"1374_CR11","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/heartjnl-2014-307200","volume":"102","author":"M Koestenberger","year":"2016","unstructured":"Koestenberger M, Apitz C, Abdul-Khaliq H, Hansmann G. Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016;102:ii14\u201322.","journal-title":"Heart."},{"key":"1374_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.echo.2010.03.019","volume":"23","author":"L Lopez","year":"2010","unstructured":"Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 2010;23:465\u201395.","journal-title":"J Am Soc Echocardiogr"},{"key":"1374_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.healun.2019.06.022","volume":"38","author":"G Hansmann","year":"2019","unstructured":"Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019;38:879\u2013901.","journal-title":"J Heart Lung Transplant"},{"key":"1374_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jpeds.2019.10.034","volume":"217","author":"PT Levy","year":"2020","unstructured":"Levy PT, Jain A, Nawaytou H, Teitel D, Keller R, Fineman J, et al. Pediatric pulmonary hypertension network (PPHNet). Risk assessment and monitoring of chronic pulmonary hypertension in premature infants. J Pediatr. 2020;217:199\u2013209.e4.","journal-title":"J Pediatr"},{"key":"1374_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1017\/S1047951115000608","volume":"26","author":"R Aswani","year":"2016","unstructured":"Aswani R, Hayman L, Nichols G, Luciano AA, Amankwah EK, Leshko JL, et al. Oxygen requirement as a screening tool for the detection of late pulmonary hypertension in extremely low birth weight infants. Cardiol Young. 2016;26:521\u20137.","journal-title":"Cardiol Young"},{"key":"1374_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(11)61621-8","volume":"379","author":"RM Berger","year":"2012","unstructured":"Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012;379:537\u201346.","journal-title":"Lancet."},{"key":"1374_CR17","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1161\/CIR.0000000000000329","volume":"132","author":"SH Abman","year":"2015","unstructured":"Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132:2037\u201399.","journal-title":"Circulation."},{"key":"1374_CR18","doi-asserted-by":"publisher","first-page":"e005336","DOI":"10.1161\/CIRCIMAGING.116.005336","volume":"10","author":"M Koestenberger","year":"2017","unstructured":"Koestenberger M, Grangl G, Avian A, Gamillscheg A, Grillitsch M, Cvirn G, et al. Normal reference values and z scores of the pulmonary artery acceleration time in children and its importance for the assessment of pulmonary hypertension. Circ Cardiovasc Imaging. 2017;10:e005336.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1374_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fped.2017.00168","volume":"5","author":"GJ Skinner","year":"2017","unstructured":"Skinner GJ. Echocardiographic assessment of pulmonary arterial hypertension for pediatricians and neonatologists. Front Pediatr. 2017;5:168.","journal-title":"Front Pediatr"},{"key":"1374_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/echo.13171","volume":"33","author":"S Abraham","year":"2016","unstructured":"Abraham S, Weismann CG. Left ventricular end-systolic eccentricity index for assessment of pulmonary hypertension in infants. Echocardiography. 2016;33:910\u20135.","journal-title":"Echocardiography."},{"key":"1374_CR21","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1016\/j.clinthera.2015.07.019","volume":"37","author":"KM Perez","year":"2015","unstructured":"Perez KM, Laughon M. Sildenafil in term and premature infants: a systematic review. Clin Ther. 2015;37:2598\u2013607.e123.","journal-title":"Clin Ther"},{"key":"1374_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809\u201318.","journal-title":"N Engl J Med"},{"key":"1374_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/2040622315590757","volume":"6","author":"CY Enderby","year":"2015","unstructured":"Enderby CY, Burger C. Medical treatment update on pulmonary arterial hypertension. Ther Adv Chronic Dis. 2015;6:264\u201372.","journal-title":"Ther Adv Chronic Dis"},{"key":"1374_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1017\/S1047951117002542","volume":"28","author":"E Aypar","year":"2018","unstructured":"Aypar E, Alehan D, Karag\u00f6z T, Aykan HH, Ertugrul \u0130. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Cardiol Young. 2018;28:542\u20137.","journal-title":"Cardiol Young"},{"key":"1374_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.118.033575","volume":"139","author":"MA Gatzoulis","year":"2019","unstructured":"Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, et al. Evaluation of Macitentan in patients with Eisenmenger syndrome. Circulation. 2019;139:51\u201363.","journal-title":"Circulation."},{"key":"1374_CR26","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.21037\/cdt.2020.04.01","volume":"10","author":"S Schweintzger","year":"2020","unstructured":"Schweintzger S, Koestenberger M, Schlagenhauf A, Grangl G, Burmas A, Kurath-Koller S, et al. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. Cardiovasc Diagn Ther. 2020;10:1675\u201385.","journal-title":"Cardiovasc Diagn Ther"},{"key":"1374_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41372-018-0303-8","volume":"39","author":"G Altit","year":"2019","unstructured":"Altit G, Bhombal S, Hopper RK, Tacy TA, Feinstein J. Death or resolution: the \u201cnatural history\u201d of pulmonary hypertension in bronchopulmonary dysplasia. J Perinatol. 2019;39:415\u201325.","journal-title":"J Perinatol"},{"key":"1374_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijcard.2015.01.038","volume":"184","author":"MJ Ploegstra","year":"2015","unstructured":"Ploegstra MJ, Zijlstra WMH, Douwes JM, Hillege HL, Berger RMF. Prognostic factors in pediatric pulmonary arterial hypertension: A systematic review and meta-analysis. Int J Cardiol. 2015;184:198\u2013207.","journal-title":"Int J Cardiol"},{"key":"1374_CR29","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41372-018-0164-1","volume":"38","author":"S Dasgupta","year":"2018","unstructured":"Dasgupta S, Aly AM, Malloy MH, Okorodudu AO, Jain SK. NTproBNP as a surrogate biomarker for early screening of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J Perinatol. 2018;38:1252\u20137.","journal-title":"J Perinatol"},{"key":"1374_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00431-019-03347-2","volume":"178","author":"P M\u00e9ndez-Abad","year":"2019","unstructured":"M\u00e9ndez-Abad P, Zafra-Rodr\u00edguez P, Lubi\u00e1n-L\u00f3pez S, Benavente-Fern\u00e1ndez I. NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants. Eur J Pediatr. 2019;178:755\u201361.","journal-title":"Eur J Pediatr"},{"key":"1374_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000442043","volume":"109","author":"AM Montgomery","year":"2016","unstructured":"Montgomery AM, Bazzy-Asaad A, Asnes JD, Bizzarro MJ, Ehrenkranz RA, Weismann CG. Biochemical screening for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Neonatology. 2016;109:190\u20134.","journal-title":"Neonatology."}],"container-title":["Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41372-022-01374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-022-01374-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-022-01374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T11:29:10Z","timestamp":1654774150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41372-022-01374-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1038\/s41372-022-01374-w","relation":{},"ISSN":["0743-8346","1476-5543"],"issn-type":[{"value":"0743-8346","type":"print"},{"value":"1476-5543","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"22 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the local ethics committee at MedUni Graz, Graz, Austria (#32\u2013135 ex 19\/20) and performed in accordance with the Declaration of Helsinki (1964) and its later amendments. Written informed consent was obtained from legal care-givers prior to inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}